Martti Vaara

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6209998/publications.pdf

Version: 2024-02-01

117625 114465 6,278 70 34 63 h-index citations g-index papers 70 70 70 4976 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Excretion of the Polymyxin Derivative NAB739 in Murine Urine. Antibiotics, 2020, 9, 143.	3.7	1
2	Title is missing!. , 2020, 15, e0232775.		0
3	Title is missing!. , 2020, 15, e0232775.		O
4	Title is missing!. , 2020, 15, e0232775.		0
5	Title is missing!. , 2020, 15, e0232775.		O
6	Title is missing!. , 2020, 15, e0232775.		0
7	Title is missing!. , 2020, 15, e0232775.		O
8	Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics. Frontiers in Microbiology, 2019, 10, 1689.	3.5	71
9	The polymyxin derivative NAB739 is synergistic with several antibiotics against polymyxin-resistant strains of Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii. Peptides, 2019, 112, 149-153.	2.4	13
10	Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics. Molecules, 2019, 24, 249.	3.8	95
11	New polymyxin derivatives that display improved efficacy in animal infection models as compared to polymyxin B and colistin. Medicinal Research Reviews, 2018, 38, 1661-1673.	10.5	32
12	Non-tuberculous Mycobacteria can Cause Disseminated Mycobacteriosis in Cats. Journal of Comparative Pathology, 2018, 160, 1-9.	0.4	3
13	Polymyxin derivatives NAB739 and NAB815 are more effective than polymyxin B in murine Escherichia coli pyelonephritis. Journal of Antimicrobial Chemotherapy, 2018, 73, 452-455.	3.0	17
14	Human kidney on a chip assessment of polymyxin antibiotic nephrotoxicity. JCI Insight, 2018, 3, .	5.0	60
15	Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	118
16	Structure–activity studies on polymyxin derivatives carrying three positive charges only reveal a new class of compounds with strong antibacterial activity. Peptides, 2017, 91, 8-12.	2.4	20
17	Increase of prostate biopsy-related bacteremic complications in southern Finland, 2005–2013: a population-based analysis. Prostate Cancer and Prostatic Diseases, 2016, 19, 417-422.	3.9	14
18	Using Chemical Probes to Assess the Feasibility of Targeting SecA for Developing Antimicrobial Agents against Gramâ€Negative Bacteria. ChemMedChem, 2016, 11, 2511-2521.	3.2	14

#	Article	IF	Citations
19	Polymyxins Targeting the Outer Membrane of Gram-negative Bacteria. Medicinal Chemistry Reviews, 2016, , 243-258.	0.1	2
20	Evaluation of Antimicrobial Therapy of Blood Culture Positive Healthcare-Associated Infections in Children. PLoS ONE, 2015, 10, e0141555.	2.5	2
21	Rapid Molecular Characterization of Acinetobacter baumannii Clones with rep-PCR and Evaluation of Carbapenemase Genes by New Multiplex PCR in Hospital District of Helsinki and Uusimaa. PLoS ONE, 2014, 9, e85854.	2.5	38
22	CP-089â€The effect of the blood culture result on subsequent antimicrobial treatment in paediatric hospital-acquired infections. European Journal of Hospital Pharmacy, 2014, 21, A36.1-A36.	1.1	0
23	The novel polymyxin derivative NAB739 is remarkably less cytotoxic than polymyxin B and colistin to human kidney proximal tubular cells. International Journal of Antimicrobial Agents, 2013, 41, 292-293.	2.5	30
24	Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. Journal of Antimicrobial Chemotherapy, 2013, 68, 636-639.	3.0	27
25	Novel derivatives of polymyxins. Journal of Antimicrobial Chemotherapy, 2013, 68, 1213-1219.	3.0	79
26	Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells. Peptides, 2012, 35, 248-252.	2.4	39
27	Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin. Journal of Antimicrobial Chemotherapy, 2010, 65, 942-945.	3.0	29
28	Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice. Journal of Antimicrobial Chemotherapy, 2010, 65, 981-985.	3.0	27
29	Polymyxins and their novel derivatives. Current Opinion in Microbiology, 2010, 13, 574-581.	5.1	87
30	Structure–activity studies on novel polymyxin derivatives that carry only three positive charges. Peptides, 2010, 31, 2318-2321.	2.4	24
31	A Novel Polymyxin Derivative That Lacks the Fatty Acid Tail and Carries Only Three Positive Charges Has Strong Synergism with Agents Excluded by the Intact Outer Membrane. Antimicrobial Agents and Chemotherapy, 2010, 54, 3341-3346.	3.2	103
32	Pharmacokinetics of novel antimicrobial cationic peptides NAB 7061 and NAB 739 in rats following intravenous administration. Journal of Antimicrobial Chemotherapy, 2009, 64, 1067-1070.	3.0	32
33	New approaches in peptide antibiotics. Current Opinion in Pharmacology, 2009, 9, 571-576.	3.5	119
34	First isolations of KPC-2-carrying ST258 Klebsiella pneumoniae strains in Finland, June and August 2009. Eurosurveillance, 2009, 14 , .	7.0	16
35	Novel Polymyxin Derivatives Carrying Only Three Positive Charges Are Effective Antibacterial Agents. Antimicrobial Agents and Chemotherapy, 2008, 52, 3229-3236.	3.2	126
36	Outer Membrane Permeability Barrier in <i>Escherichia coli</i> Mutants That Are Defective in the Late Acyltransferases of Lipid A Biosynthesis. Antimicrobial Agents and Chemotherapy, 1999, 43, 1459-1462.	3.2	113

3

#	Article	IF	CITATIONS
37	Poor Antibacterial Effect of RopivacaineÂ. Anesthesiology, 1999, 91, 884-884.	2.5	73
38	Phosphate groups in lipopolysaccharides of Salmonella typhimurium rfa Pmutants. FEBS Letters, 1997, 409, 457-460.	2.8	9
39	Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria. Antimicrobial Agents and Chemotherapy, 1996, 40, 1801-1805.	3.2	188
40	Overgrowth of Enterococcus faecium in the Feces of Patients with Hematologic Malignancies. Clinical Infectious Diseases, 1996, 23, 694-697.	5.8	33
41	Lipopolysaccharides of polymyxin B-resistant mutants of Escherichia coii are extensively substituted by 2-aminoethyl pyrophosphate and contain aminoarabinose in lipid A. Molecular Microbiology, 1995, 16, 271-278.	2.5	185
42	Low Levels of Cytokines and Endotoxin in a Fatal Case of Myocardial Depression and Septic Shock Due to Yersinia pseudotuberculosis. Scandinavian Journal of Infectious Diseases, 1995, 27, 533-535.	1.5	4
43	Ability of cecropin B to penetrate the enterobacterial outer membrane. Antimicrobial Agents and Chemotherapy, 1994, 38, 2498-2501.	3.2	44
44	Increased substitution of phosphate groups in lipopolysaccharides and lipid A of the polymyxin-resistant pmrA mutants of Salmonella typhimurium: a31P-NMR study. Molecular Microbiology, 1994, 11, 481-487.	2.5	162
45	Chemical Structure of the Lipid A Component of Lipopolysaccharides of the Genus Pectinatus. FEBS Journal, 1994, 224, 63-70.	0.2	21
46	Defective biosynthesis of the lipid A component of temperature-sensitive firA (omsA) Mutant of Escherichia coli. FEBS Journal, 1993, 212, 363-369.	0.2	15
47	Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria. Antimicrobial Agents and Chemotherapy, 1993, 37, 354-356.	3.2	151
48	Antibiotic-supersusceptible mutants of Escherichia coli and Salmonella typhimurium. Antimicrobial Agents and Chemotherapy, 1993, 37, 2255-2260.	3.2	160
49	Preferential synthesis of heptaacyl lipopolysaccharide by the ssc permeability mutant of Salmonella typhimurium. FEBS Journal, 1992, 204, 1101-1106.	0.2	17
50	Eight bacterial proteins, including UDP-N-acetylglucosamine acyltransferase (LpxA) and three other transferases of Escherichia coli, consist of a six-residue periodicity theme. FEMS Microbiology Letters, 1992, 97, 249-254.	1.8	43
51	Agents that increase the permeability of the outer membrane Microbiological Reviews, 1992, 56, 395-411.	10.1	925
52	Agents that increase the permeability of the outer membrane. Microbiological Reviews, 1992, 56, 395-411.	10.1	1,468
53	The outer membrane permeability-increasing action of linear analogues of polymyxin B nonapeptide. Drugs Under Experimental and Clinical Research, 1991, 17, 437-43.	0.3	12
54	Antimicrobial susceptibility of Salmonella typhimurium carrying the outer membrane permeability mutation SS-B. Antimicrobial Agents and Chemotherapy, 1990, 34, 853-857.	3.2	22

#	Article	IF	CITATIONS
55	Bacterial â€~histone-like protein l' (HLP-I) is an outer membrane constituent?. FEBS Letters, 1990, 262, 123-126.	2.8	37
56	Do salicylates and ascorbate increase the outer membrane permeability to hydrophobic antibiotics in Pseudomonas aeruginosa?. Drugs Under Experimental and Clinical Research, 1990, 16, 569-74.	0.3	2
57	Sodium hexametaphosphate sensitizes Pseudomonas aeruginosa, several other species of Pseudomonas, and Escherichia coli to hydrophobic drugs. Antimicrobial Agents and Chemotherapy, 1989, 33, 1741-1747.	3.2	48
58	rfaP mutants of Salmonella typhimurium. FEBS Journal, 1989, 185, 541-546.	0.2	45
59	A Novel Enzyme Application for Corn Wet Milling. Starch/Staerke, 1988, 40, 409-411.	2.1	34
60	Effect of small cationic leukocyte peptides (defensins) on the permeability barrier of the outer membrane. Infection and Immunity, 1988, 56, 2324-2329.	2.2	50
61	Susceptibility of Gram-negative bacteria to the synergistic bactericidal action of serum and polymyxin B nonapeptide. Canadian Journal of Microbiology, 1986, 32, 66-69.	1.7	16
62	Susceptibility of gram-negative bacteria to polymyxin B nonapeptide. Antimicrobial Agents and Chemotherapy, 1984, 25, 701-705.	3.2	103
63	An outer membrane-disorganizing peptide PMBN sensitizes E. coli strains to serum bactericidal action. Journal of Immunology, 1984, 132, 2582-9.	0.8	43
64	Polycations sensitize enteric bacteria to antibiotics. Antimicrobial Agents and Chemotherapy, 1983, 24, 107-113.	3.2	216
65	Sensitization of Gram-negative bacteria to antibiotics and complement by a nontoxic oligopeptide. Nature, 1983, 303, 526-528.	27.8	232
66	Characterization of the lipopolysaccharide from the polymyxinâ€resistant <i>pmrA</i> mutants of <i>Salmonella typhimurium</i> . FEBS Letters, 1981, 129, 145-149.	2.8	198
67	Outer Membrane Permeability Barrier Disruption by Polymyxin in Polymyxin-Susceptible and -Resistant <i>Salmonella typhimurium</i> . Antimicrobial Agents and Chemotherapy, 1981, 19, 578-583.	3.2	109
68	Increased outer membrane resistance to ethylenediaminetetraacetate and cations in novel lipid A mutants. Journal of Bacteriology, 1981, 148, 426-434.	2.2	102
69	Two Improved Methods for Obtaining Axenic Cultures of Cyanobacteria. Applied and Environmental Microbiology, 1979, 38, 1011-1014.	3.1	75
70	Decreased binding of polymyxin by polymyxin-resistant mutants of Salmonella typhimurium. Journal of Bacteriology, 1979, 139, 664-667.	2.2	85